Programs Pipeline

Sirona Biochem / TFChem, specialize in the improvement and development of carbohydrate-based molecules through fluorination. Carbohydrate-based molecules offer immense commercial potential for cosmetics and therapeutics. Sirona is currently focused on advancing three programs –cosmetic agents, therapeutics and biological ingredients.  The two most advanced programs include the  cosmetic skin lightener  and diabetes drug. Other ongoing projects include the development and commercial opportunities for the Glycoprotein library and the synthesis of a compound for acne treatment.

Sirona Biochem has made significant advancements in the area of skin lightening. Recognized for scientific innovation at the laboratory in France, the French government awarded the Company an innovation grant worth CDN$1.9 Million to develop the cosmetic skin lightener program to a commercial ready stage.  Since then, numerous efficacy and stability studies have been completed with results showing superiority over popular commercial products.  In 2018, Sirona signed a non-exclusive agreement with Rodan + Fields, the leading skin care brand in the United States[1], for the licensing and commercial sales of novel ingredient TFC-1067 to brighten and even skin tone. Rodan and Fields will be the first to market for a consumer product utilizing TFC-1067 in certain countries including United States.

The Company has a library of skin lightening compounds and remains in partnering discussions for the compound TFC-1067.

The sodium glucose co-transporter (SGLT) inhibitor for diabetes, achieved positive preclinical results. In a head-to-head preclinical study, Sirona Biochem’s SGLT inhibitor performed better than Johnson and Johnson’s canagliflozin (Invokana™), which was given FDA market approval in the U.S. (March 2013) and in Europe (November 2013).  In 2014, Sirona licensed the SGLT2 Inhibitor to Wabang Biopharmaceuticals for development and commercialization of this anti-diabetic inhibitor exclusively in the People’s Republic of China (PRC). In exchange for this license, Wanbang Biopharma has provided an upfront and will give milestone payments of up to US$9.5M in addition to royalty payments for product sales. Wanbang is currently in Phase I clinical studies and advancing ahead of schedule.

Extensive research and development remains underway for the Glycoprotein library. These compounds have shown a role in protection of cells under different stressors, including UV, starvation and oxidative conditions. The lab at TFChem and several CROs are performing assays and analyses of the compounds to move them towards commercialization. Current cosmetic indications of the portfolio include keloid and stress protection creams, along with a potential role as an adjuvant in cell preservation solutions.

Sirona Biochem’s proprietary chemistry technology has relevance in many therapeutic, cosmetic and biological areas where the potential for development is high.


[1] Source Euromonitor International Limited; Beauty and Personal Care 2019 Edition, retail value RSP terms; all channels, Skincare includes Sets & Kits